Orion Portfolio Solutions LLC Acquires 171 Shares of Humana Inc. (NYSE:HUM)

Orion Portfolio Solutions LLC lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,834 shares of the insurance provider’s stock after purchasing an additional 171 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Humana were worth $1,226,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HUM. FPC Investment Advisory Inc. bought a new position in Humana during the fourth quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Humana in the 4th quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. boosted its position in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 4.6 %

NYSE HUM opened at $253.37 on Friday. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a market capitalization of $30.58 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 2.05 and a beta of 0.62. The stock’s 50 day moving average is $267.58 and its two-hundred day moving average is $272.13. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.40%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HUM. Piper Sandler lifted their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Truist Financial boosted their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. JPMorgan Chase & Co. lowered their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Eighteen analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $280.17.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.